Lucid Drone Technologies Taps T-Mobile to Power Commercial Cleaning Drones
25.4.2022 16:23:00 EEST | Business Wire | Press release
Today, T-Mobile (NASDAQ: TMUS) announced that Lucid Drone Technologies has chosen the Un-carrier to be the exclusive provider of IoT connectivity and management for their fleet of industrial spraying drones. Together, Lucid Drone Technologies and T-Mobile are collaborating to put maintenance teams and exterior cleaning companies out of harm’s way using drone technology for high-risk facilities maintenance work like exterior soft-wash cleaning and high-rise window washing. The companies also plan to leverage T-Mobile's industry-leading 5G network in the future to fly drones beyond line-of-sight and power more data-intensive capabilities like video streaming.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220424005109/en/
Lucid Drone Technologies has chosen T-Mobile as the exclusive provider of IoT connectivity and management for their growing fleet of industrial spraying drones that provide commercial cleaning services.
A game changer for safety of maintenance teams
Commercial property management firms and developers make significant investments to keep maintenance teams safe. Expensive liability insurance premiums and equipment fees have facilities leaders looking for new and cost-effective solutions. Enter industrial spraying drone pioneer Lucid Drone Technologies and the Un-carrier to deliver a game changer — drones equipped to clean exterior building surfaces and windows.
The next generation of Lucid Drone Technologies industrial spraying drones, powered by T-Mobile for Business, can perform exterior washing for commercial building surfaces and windows, including outdoor stadiums and arenas, hotels, and university structures. That means maintenance teams can steer clear of some high-risk tasks, keeping them safer and focused on other mission critical work.
IoT driving the future of industrial spraying drone technology
T-Mobile’s network powers critical capabilities for Lucid Drone Technologies industrial spraying drones such as real-time sharing of flight data, battery utilization information, hardware diagnostics, and delivery of firmware and software updates. Additionally, T-Mobile Control Center will give Lucid Drone Technologies the ability to view and manage the connectivity of their industrial spraying drones. With the automation and provisioning capabilities of T-Mobile’s IoT platform, Lucid Drone Technologies can easily accelerate deployment of their growing fleet. Lucid Drone Technologies will have near real-time visibility to all their industrial spraying drones with the ability to monitor network conditions and device behavior with T-Mobile Control Center.
Initially, T-Mobile for Business will deliver 4G LTE connectivity to Lucid Drone Technologies industrial spraying drones, providing a reliable connection nationwide. Lucid Drone Technologies expects to utilize the Un-carrier's 5G network in the near future for advanced use cases such as network operations center access, live streaming video and remote piloting. As Americas largest and fastest 5G network, T-Mobile is poised to push IoT to its full potential and catapult adoption — paving the way for new drone applications that rely on low-latency, high-speed data, and real-time location and proximity-based services.
"At Lucid Drone Technologies, we are committed to providing robotic solutions that allow our customers to complete jobs that were once dull, dirty, and dangerous in a safer, faster, and smarter way,” said Andrew Ashur, CEO, Lucid Drone Technologies. “T-Mobile not only allows us to provide our customers with the highest quality of real-time support and connectivity today, but they also have impressive 5G capabilities that allow us to push the frontier limits of responsible robotics."
“Lucid Drone Technologies is a great example of a customer using originality and new technology to solve complicated problems,” said Callie Field, President, T-Mobile Business Group. “It’s not very often that you get to collaborate with these kinds of thinkers, and we’re thrilled to have the opportunity to offer our technology to help bring their vision to life.”
To learn more about Lucid Drone Technologies, visit: www.luciddronetech.com
For more information about IoT from T-Mobile for Business, go to: www.t-mobile.com/business/solutions/iot
Follow T-Mobile’s Official Twitter Newsroom @TMobileNews to stay up to date with the latest company news.
Fastest based on median, overall combined 5G speeds according to analysis by Ookla® of Speedtest Intelligence® data 5G download speeds for Q1 2022. Ookla trademarks used under license and reprinted with permission.
About T-Mobile
T-Mobile U.S. Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile, Metro by T-Mobile and Sprint. For more information please visit: https://www.t-mobile.com.
About Lucid Drone Technologies
Lucid Drone Technologies is a Charlotte, NC-based robotics company that currently designs and builds industrial spraying drones for labor-intensive jobs. Lucid Drone Technologies was started in 2018, and set out to provide a Safer, Faster, and Smarter alternative to traditional dull, dirty, and dangerous jobs.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220424005109/en/
Contact information
Media Contacts
T-Mobile US, Inc. Media Relations
MediaRelations@t-mobile.com
Lucid Drone Technologies
John Dry
jdry@luciddronetech.com
Investor Relations Contact
T-Mobile US, Inc.
investor.relations@t-mobile.com
https://investor.t-mobile.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
